MetaCap

Regeneron Pharmaceuticals (REGN) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Takeda Pharmaceutical (TAK) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 52.2% versus a gain of 21.8%. Over five years, TAK leads with a +60.9% price change compared with +43.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($95.24 billion vs $69.55 billion), about 1.4 times the size.

On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.8x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 0.40%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

REGN+21.80%TAK+52.24%
+56%+16%-24%
Nov 21, 20251 yearNov 20, 2026
REGN+41.06%TAK+55.39%
+89%+29%-30%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

REGN versus TAK key metrics
MetricREGNTAK
Share price$920.69$21.77
Market cap$95.24B$69.55B
1-day change-0.19%+1.68%
YTD return+19.28%+39.64%
1-year return+21.80%+52.24%
5-year return+43.11%+60.90%
P/E ratio (TTM)20.35311.00
Forward P/E12.8541.08
EPS (TTM)$45.24$0.07
Dividend yield0.40%927.88%
Annual dividend$3.70$202.00
Revenue (latest FY)$14.34B—
Revenue growth (YoY)+0.99%—
Net income (latest FY)$4.50B—
Operating margin24.95%—
Net margin31.41%—
52-week high$991.73$22.07
52-week low$591.52$14.16
Distance from 52-week high-7.16%-1.36%
Analyst consensusbuystrong_buy
Avg. price target upside+7.64%+12.68%
Average volume805.45K2.73M
Shares outstanding101.63M3.19B
Employees15,41047,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TAK has outperformed REGN by 30.4 percentage points over the past year.
  • Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 20.4x trailing P/E).
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.40%).

About Regeneron Pharmaceuticals

REGN stock →

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

REGN vs TAK FAQ

Which is bigger, Regeneron Pharmaceuticals or Takeda Pharmaceutical?

Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $95.24B compared with $69.55B for Takeda Pharmaceutical (TAK).

Which stock has performed better over the past year, REGN or TAK?

TAK returned +52.24% over the past 12 months, compared with +21.80% for REGN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, REGN or TAK?

REGN has the lower trailing P/E at 20.4, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Regeneron Pharmaceuticals or Takeda Pharmaceutical?

Takeda Pharmaceutical has the higher yield at 927.88%, compared with 0.40% for Regeneron Pharmaceuticals.

Are Regeneron Pharmaceuticals and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons